Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Padcev-Keytruda Pair Makes Mark in Cisplatin-Eligible MIBC: Astellas
Astellas Pharma said on December 17 that Padcev (enfortumab vedotin) plus Keytruda (pembrolizumab) has now delivered a survival win in cisplatin-eligible muscle-invasive bladder cancer (MIBC), after a PIII perioperative trial showed the regimen significantly improved outcomes versus standard cisplatin-based chemotherapy.…
To read the full story
Related Article
- Astellas, MSD File Padcev-Keytruda for Cisplatin-Eligible MIBC in Japan
May 15, 2026
- Padcev-Keytruda Gets FDA Priority Review for Cisplatin-Eligible Perioperative MIBC
April 22, 2026
- Padcev-Keytruda under EMA Review for Cisplatin-Eligible Perioperative MIBC
March 24, 2026
- Astellas, MSD Seek Japan Nod for Padcev/Keytruda in Perioperative MIBC
February 2, 2026
- Padcev/Keytruda Wins US Nod for Perioperative Bladder Cancer Use
November 26, 2025
- Padcev/Keytruda Label Expansion Accepted for US FDA Review
October 23, 2025
- Padcev-Keytruda Combo Delivers Positive PIII Data in Bladder Cancer
August 18, 2025
BUSINESS
- Takeda CEO Says Orzeyful Could Redefine NT1 Standard of Care
July 31, 2026
- Pfizer Seeks Pediatric Expansion for Hympavzi in Japan
July 31, 2026
- Nippon Shinyaku Exercises Option for AB2 Bio’s Tadekinig Alfa in US
July 31, 2026
- Alfresa Takes Stake in Ember to Bolster Pharma Cold Chain in Japan
July 31, 2026
- Sanwa Kagaku Says Kumamoto Plant Remains Shut, Drug Supplies Stable
July 31, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…